Article Text

Download PDFPDF
H2FPEF score predicts 1-year rehospitalisation of patients with heart failure with preserved ejection fraction
  1. Yifei Tao,
  2. Wenjing Wang,
  3. Jing Zhu,
  4. Tao You,
  5. Yi Li,
  6. Xiang Zhou
  1. Department of Cardiology, Second Affiliated Hospital of Soochow University, Suzhou, China
  1. Correspondence to Dr Xiang Zhou, Second Affiliated Hospital of Soochow University, Suzhou 215004, China; zhou-xiang{at}suda.edu.cn

Abstract

Background Heart failure with preserved ejection fraction (HFpEF) has received widespread attention in recent years. There is currently a lack of valuable predictors for the prognosis of this disease. Here, we aimed to identify a non-invasive scoring system that can effectively predict 1-year rehospitalisation for patients with HFpEF.

Methods We included 151 consecutive patients with HFpEF in a prospective cohort study and investigated the association between H2FPEF score and 1-year readmission for heart failure using multivariate Cox regression analysis.

Results Our findings indicated that obesity, age >70 years, treatment with ≥2 antihypertensives, echocardiographic E/e’ ratio >9 and pulmonary artery pressure >35 mm Hg were independent predictors of 1-year readmission. Three models (support vector machine, decision tree in R and Cox regression analysis) proved that H2FPEF score could effectively predict 1-year readmission for patients with HFpEF (area under the curve, 0.910, 0.899 and 0.771, respectively; p<0.001).

Conclusion Our study demonstrates that the H2FPEF score has excellent predictive value for 1-year rehospitalisation of patients with HFpEF.

  • heart failure
View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @no

  • YT, WW and JZ contributed equally.

  • Contributors YT, WW and JZ performed the study and wrote the manuscript. TY and YL carried out the statistical analysis. XZ designed the study and revised the manuscript.

  • Funding This work was supported by the Scientific Research Program for Young Talents of China National Nuclear Corporation (51001).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.